Cochrane Abstracts
Belimumab for systemic lupus erythematosus
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Belimumab for Systemic Lupus Erythematosus." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438479/all/Belimumab_for_systemic_lupus_erythematosus.
Belimumab for systemic lupus erythematosus. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438479/all/Belimumab_for_systemic_lupus_erythematosus. Accessed November 22, 2024.
Belimumab for systemic lupus erythematosus. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438479/all/Belimumab_for_systemic_lupus_erythematosus
Belimumab for Systemic Lupus Erythematosus [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 November 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438479/all/Belimumab_for_systemic_lupus_erythematosus.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Belimumab for systemic lupus erythematosus
ID - 438479
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438479/all/Belimumab_for_systemic_lupus_erythematosus
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
